Dexcom Adjusts Full-Year Revenue Outlook Following 13% Growth in Second Quarter
Dexcom reported second-quarter revenue of approximately $1.3 billion, reflecting a year-over-year increase of 13%. Based on this performance, the company has slightly raised its full-year revenue outlook to between $5.18 billion and $5.25 billion for 2026, up from previous guidance of $5.16 billion to $5.25 billion. The stock price rose by over 8% following the earnings report as investors reacted positively to Dexcom's updated forecast and recent product developments. Notably, in June 2026, the FDA approved Dexcom’s Stelo glucose biosensor system for children, marking a significant milestone as it is the first OTC CGM cleared for pediatric use. Dexcom also shared positive clinical data from its G7 device at the American Diabetes Association's Scientific Sessions. The CONNECT trial showed that patients using G7 experienced an average A1C reduction of 1.6% over 26 weeks, outperforming a self-monitoring control group.
Tickers: $DXCM
Topics: CGM technology FDA approval medical devices revenue growth